Alten, R., Batko, B., Hala, T., Kameda, H., Radominski, S. C., Tseluyko, V., . . . Cohen, S. (2019). Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: Efficacy, safety and immunogenicity from week 30 to week 54. RMD Open.
Chicago Stili AlıntıAlten, Rieke, et al. "Randomised, Double-blind, Phase III Study Comparing the Infliximab Biosimilar, PF-06438179/GP1111, With Reference Infliximab: Efficacy, Safety and Immunogenicity From Week 30 to Week 54." RMD Open 2019.
MLA AlıntıAlten, Rieke, et al. "Randomised, Double-blind, Phase III Study Comparing the Infliximab Biosimilar, PF-06438179/GP1111, With Reference Infliximab: Efficacy, Safety and Immunogenicity From Week 30 to Week 54." RMD Open 2019.